Portal de Periódicos da CAPES

Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer

2016; Elsevier BV; Volume: 15; Issue: 1 Linguagem: Inglês

10.1016/j.clgc.2016.08.006

1938-0682

Timothy C. Flynn, Elizabeth A. Guancial, Maria Kilari, Deepak Kilari,

Prostate Cancer Diagnosis and Treatment

Androgen receptor (AR) signaling pathway inhibition has been the mainstay of treatment for men with systemic prostate cancer (PC) since Charles Huggins' seminal publication in 1941.1 Even in men with metastatic castrate-resistant prostate cancer (mCRPC), disease progression is androgen-driven, as demonstrated by the overall survival advantage noted with abiraterone acetate (AA) and enzalutamide (enza), agents that interfere with either androgen biosynthesis or AR signaling, respectively, and the observation that progressive castrate-resistant prostate cancer (CRPC) is typically characterized by a rising prostate-specific antigen (PSA).